These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 6666224)
21. Antianginal efficacy of long-term nitrate therapy. Kenedi P; Giebeler B Z Kardiol; 1983; 72 Suppl 3():233-8. PubMed ID: 6666227 [TBL] [Abstract][Full Text] [Related]
22. [Influence of combination therapy (isosorbide dinitrate and molsidomine) on the incidence of angina pectoris in patients with coronary heart disease]. Ciopor M; Fischer A; Turina J; Hess OM Praxis (Bern 1994); 1997 Nov; 86(47):1849-53. PubMed ID: 9480502 [TBL] [Abstract][Full Text] [Related]
23. The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance. Silber S; Vogler AC; Krause KH; Theisen K Drugs; 1987; 33 Suppl 4():69-79. PubMed ID: 3622317 [TBL] [Abstract][Full Text] [Related]
24. Sustained antianginal efficacy of oral high-dose isosorbide dinitrate in patients with coronary heart disease. Schneider W; Wietschoreck A; Bussmann WD; Kaltenbach M Z Kardiol; 1983; 72 Suppl 3():259-67. PubMed ID: 6666231 [TBL] [Abstract][Full Text] [Related]
25. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Straka RJ; Fish JT; Benson SR; Suh JT Pharmacotherapy; 1997; 17(1):126-32. PubMed ID: 9017773 [TBL] [Abstract][Full Text] [Related]
26. Circadian investigation of interval therapy with isosorbide dinitrate in coronary heart disease. Wortmann A; Bachmann K; Meinhold M Eur Heart J; 1988 Jan; 9 Suppl A():119-24. PubMed ID: 3409908 [TBL] [Abstract][Full Text] [Related]
27. Can the problem of nitrate tolerance be solved? Silber S Z Kardiol; 1985; 74 Suppl 1():51-4. PubMed ID: 3993162 [No Abstract] [Full Text] [Related]
28. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease. Grabczewska Z; Białoszyński T; Szymański P; Sukiennik A; Swiatkiewicz I; Koziński M; Kochman W; Grześk G; Kubica J Cardiol J; 2008; 15(4):344-50. PubMed ID: 18698543 [TBL] [Abstract][Full Text] [Related]
29. Anti-ischemic effects of first and second dose of 20 mg isosorbide dinitrate administered 5 hours apart: attenuation of effects despite rising plasma concentration. Lehmann G; Reiniger G; Wolf H; Beyerle A; Rudolph W Cardiovasc Drugs Ther; 1995 Apr; 9(2):339-45. PubMed ID: 7662601 [TBL] [Abstract][Full Text] [Related]
30. Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations. Galeazzi RL; Platzer R; Reutemann G Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):387-93. PubMed ID: 6629543 [TBL] [Abstract][Full Text] [Related]
31. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration. Dulac O; Alvarez JC Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218 [TBL] [Abstract][Full Text] [Related]
32. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Kisicki JC; Fiske K; Lyne A Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196 [TBL] [Abstract][Full Text] [Related]
33. Nisoldipine versus isosorbide dinitrate in coronary heart disease: results of a double-masked study. Heublein B; Amende I; Blanke PM; Baunack-Frost AR; Breuer HW Clin Ther; 1996; 18(3):448-59. PubMed ID: 8829020 [TBL] [Abstract][Full Text] [Related]
34. Anti-ischemic effects of slow-release formulations of nifedipine, isosorbide-5-mononitrate and their combination in patients with coronary heart disease. Erlemeier HH; Kupper W; Hempel NB; Bleifeld W Cardiology; 1988; 75(6):409-18. PubMed ID: 3228824 [TBL] [Abstract][Full Text] [Related]
35. Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. Stegaru B; Loose R; Keller H; Buss J; Wetzel E Am J Cardiol; 1988 Mar; 61(9):74E-77E. PubMed ID: 3348141 [TBL] [Abstract][Full Text] [Related]
36. [Nitrates in ischemic heart disease: the dependence of the effect on the route of administration and dosage of the preparation]. Metelitsa VI; Martsevich SIu; Piotrovskiĭ VK; Kokurina EV Kardiologiia; 1985 Nov; 25(11):119-20. PubMed ID: 3936963 [No Abstract] [Full Text] [Related]
37. [Use of isonit (nitrosorbide) in the treatment of ischemic heart disease]. Zamotaev IP; Venediktova MG; Lozinskiĭ LG; Sandomirskiĭ BL Klin Med (Mosk); 1986 Jun; 64(6):28-33. PubMed ID: 3747432 [No Abstract] [Full Text] [Related]
38. Antiischemic effects of a newly developed capsule containing 120 mg isosorbide dinitrate in sustained release form. Silber S; Vogler AC; Spiegelsberger F; Vogel M; Theisen K Am J Cardiol; 1988 Jun; 61(15):1352-3. PubMed ID: 3287887 [No Abstract] [Full Text] [Related]
39. [The potential toxic action of the excipient of delayed-release isosorbide dinitrate]. Castell JV; Gómez-Lechón MJ; Mayordomo F Rev Esp Cardiol; 1986; 39(3):220-6. PubMed ID: 3738107 [No Abstract] [Full Text] [Related]
40. [Anti-angina effectiveness of isosorbide dinitrate in an acute trial and following continuous 4-week therapy with 40 mg 6 times a day]. Schneider W; Wietschoreck A; Bussmann WD; Kaltenbach M Klin Wochenschr; 1985 May; 63(10):460-7. PubMed ID: 3925217 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]